ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Amyloid Hypothesis gaining strength

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jul 17, 2023 8:39pm

219 Views

Post# 35545212

RE:Amyloid Hypothesis gaining strength

Ha, I don't know if congrats are in order just yet. We're back to just below what we were at when PMN hit the NASDAQ.

However, today was a pleasant surprise. Just worried about the inevitable slide until the next round of news.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs